Dr. Frank Naus is the Chief Operating Officer of Allphase Clinical Research Inc., a Canadian CRO headquartered in Ottawa, Ontario. Frank earned his Doctorate in Business Administration from Walden University and has an MBA from Wilfrid Laurier University and MSc and BSc degrees in Applied Health Sciences from the University of Waterloo. Frank started his career in the pharmaceutical and clinical research industry. Prior to joining Allphase, he was Vice President Research at Hamilton Health Sciences.

Dr. Anne Mullin works with leading decision-makers across the health and life sciences sector to amplify the impact of biomedical discoveries and healthcare innovations on the health and wellbeing of populations in both developed and developing countries.

​Anne’s collaborative approach to working with clients and rich academic track record in the study of infectious disease have supported the sustainability and success of numerous international product development consortia, allowed both industry and academic partners to manage risk of high-impact clinical trials, and helped clients from industry, academia and the not-for-profit sector attract capital, establish partnerships and drive innovation. Having led engagements in North America, Europe, Southeast Asia and Africa, Anne’s client base spans the globe.

Dr. Andy J. Smith is the President and Chief Executive Officer of Sunnybrook Health Sciences Centre in Toronto, Ontario. In addition, he is a Professor of Surgery at the University of Toronto. He completed medical school, including a Masters of Science, and General Surgery residency at the University of Toronto. He also completed a Surgical Oncology Fellowship at Memorial Sloan – Kettering Cancer Center in New York. Upon returning to Canada, he established himself as a leader in the management of colorectal cancer. He has served as Head of the Division of General Surgery at Sunnybrook, Chair of the Division of General Surgery at the University of Toronto and Chief of the Odette Cancer Program and Regional Vice President for Cancer Care Ontario. Most recently, Dr. Smith has served Sunnybrook as its Executive Vice President, Chief Medical Executive.

Drew Memmott is currently the Senior Vice President for Research Administration at Dana-Farber Cancer Institute and Associate Director for Administration for the Dana-Farber/Harvard Cancer Center, a National Cancer Institute (NCI) designated Comprehensive Cancer Center comprised of 5 Harvard-affiliated teaching hospitals and 2 Harvard biomedical schools. He is the senior administrative leader for all aspects of research at DFCI and the DF/HCC consortium. In his role as SVP he is responsible for oversight of the research administrative infrastructure (including grant and contract management, core facilities, laboratory operations, and the animal resource facility) and clinical research operations (including clinical trials administration and operations, Institutional Review Board, protocol review approval and activation, and clinical trials financial management). In his role as Associate Director for Administration for DF/HCC he oversees the administration of the DF/HCC Cancer Center Support Grant and its associated operational requirements including administration, shared resources, and clinical research support.
Prior to DFCI Drew held a number of senior leadership roles at Mayo Clinic. He was the Associate Director for Administration for the Mayo Clinic Comprehensive Cancer Center, an NCI designated national cancer center with operations in three geographic regions. Additionally, Drew also served as a Director of Research Administration at Columbia University Medical Center.
Drew is an active member of the Cancer Center Administrator’s Forum (CCAF), an organization of NCI designated Cancer Center Administrators; the Association of American Cancer Institutes (AACI); an External Advisory Board Member for several NCI designated cancer centers; and the National Council of University Research Administrators (NCURA) where he has served in multiple committee leadership roles.

Charles Weijer is Professor and Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University in London, Canada. He is the leading expert on the ethics of randomized controlled trials. In 2008, Charles founded the Rotman Institute of Philosophy, which is dedicated to fostering collaboration between the humanities and the sciences, and served as the Institute’s first director. In 2014, he received Western’s Hellmuth Prize for Achievement in Research, and, in 2016, he was elected to the Royal Society of Canada

Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO), the industry voice for the life sciences sector in Ontario. Jason obtained his PhD in Chemistry from the University of Massachusetts and his undergraduate degree from the University of Waterloo. Following graduate school, Jason returned to Ontario and worked in the pharmaceutical industry as a research scientist developing scalable manufacturing processes of active pharmaceutical ingredients.

Monica Taljaard is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI) and Associate Professor in the School of Epidemiology and Public Health at the University of Ottawa. She received her PhD degree in Epidemiology and Biostatistics at Western University in 2006. Her main research interests are in the design, analysis and ethics of cluster randomized trials. As a methodologist with the Ottawa Methods Centre, she works with clinicians and researchers from a variety of disciplines and medical specialties in the design and analysis of cluster randomized trials, standard clinical trials, and observational studies. She supervises MSc and PhD students in Epidemiology and teaches Biostatistics courses at the University of Ottawa.

Dr Carole Légaré completed her medical training at the University of Ottawa, and her postgraduate pharmacoepidemiology and pharmacovigilance training at the London School of Hygiene and Tropical Medicine in the UK. After gaining experience in clinical practice and public health, she joined Health Canada in 2002 where she initially worked in pharmacovigilance.  She also worked as a senior medical advisor for the Centre for Biologics Evaluation during the H1N1 influenza pandemic.   In 2013, she joined the Therapeutic Products Directorate as the Director of the Office of Clinical Trials, where she oversees all activities related to the approval and pharmacovigilance of clinical trials involving pharmaceuticals.  She is currently a member of the ICH E8 working group on General Considerations for Clinical Studies.

Dr Mark Clemons graduated from the University of Newcastle upon Tyne, U.K. (B.Med.Sci; MB BS). He completed his post-doctoral training in internal medicine and medical oncology at the Hammersmith Hospital, London; Christie Hospital, Manchester (MSc, Oncology; MD, Oncology) and at the Princess Margaret Hospital, Toronto. He is a Clinical Investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program), staff medical oncologist (Ottawa Hospital Cancer Centre) and Professor of Medicine (University of Ottawa). He is the recipient of multiple peer-reveiwed research grants and is widely published in the field of breast cancer management. His publications also reflect eclectic topics such as; retirement planning, excessive oncologist travel, oncologist quality of life and issues such as preventing spam. His current research vision is to remove many of the barriers that lead the development of multiple standard of care therapies with very little data to actually show which treatment is best in the real world setting.

Dr. Lisa Goos is the Director of Clinical Research Services at The Hospital for Sick Children. Lisa received her Ph.D. in cognitive psychology from York University, and was a CIHR Postdoctoral Fellow in the Program in Neurosciences and Mental Health at The Hospital for Sick Children. Her area of research specialization was the influence of epigenetic regulatory mechanisms on cognitive development and behaviour. Dr. Goos has also worked and published extensively in the area of genetic communications, helping scientists and non-scientists engage in informed dialogue and decision-making on the basis of genetic information. In senior strategic and operational research administration positions for over 10 years, Lisa has developed both corporate and divisional strategic plans, led teams through the completion of large strategic projects, and implemented operational systems and procedures to support effective management of the research enterprise. An exceptional corporate change agent, Lisa has driven development in the strategic and functional capacity necessary to enable knowledge translation, and facilitated research integration with practice across healthcare, legal and academic settings.